Examining the prevalence of hepatic steatosis and advanced fibrosis using non-invasive measures across Canada: A national estimate using the Canadian Health Measures Survey (CHMS) from 2009-2019

Abstract

Introduction and Objectives

Prevalence estimates are crucial for enhancing preparedness to prevent and manage chronic diseases. This is the first study to estimate the prevalence of hepatic steatosis and advanced fibrosis in Canada, leveraging a nationally representative survey and multiple validated non-invasive tests (NITs).

Materials and Methods

The Canadian Health Measures Survey (CHMS) is Canada's largest direct health measures survey, which collects data on sociodemographic, clinical factors, and blood chemistry. We determined steatosis using two NITs: the Hepatic Steatosis Index (HSI) and the NAFLD Ridge Score (NRS). The FIB-4 Index and NAFLD fibrosis score (NFS) were used to assess the risk of advanced fibrosis among adults with steatosis. Survey weights were incorporated to account for oversampling, survey nonresponse, and post-stratification.

Results

Between 2009 and 2019, 1365 children (55 % males, median age 13 (IQR: 10–15) and 4664 adults (51 % males, median age 45 (IQR: 34–62), 57 % reporting weekly alcohol consumption) were included in our study. The weighted steatosis prevalence ranged from 9 to 11 % among children to 38–48 % among adults based on the NRS and HSI, respectively. Between 86–87 % of adults with type 2 diabetes and 65–72 % with hypertension had evidence of steatosis. Overall, 1.2–2.4 % of adults with steatosis were at risk of advanced liver fibrosis.

Conclusions

We estimate between 1 in 3 and 1 in 2 adults have hepatic steatosis, and 195,000–406,200 are at high risk of advanced liver fibrosis in Canada. No routine screening guidelines for liver fibrosis exist in Canada, and most patients are unaware of their condition. Prevalence studies are essential for raising awareness and advocating for the inclusion of steatotic liver disease on national public health agendas.